Medtronic and Abbott have agreed not to sue each other over stent technology, thanks to Medtronic's offer to pay $400 million to Abbott. The settlement resolves all outstanding intellectual property litigation between the two medical device makers, who agreed not to sue each other again in the area of coronary stent and stent delivery systems for at least 10 years. Medtronic said it will also pay $42 million to evYsio Medical Devices as part of a sublicense to Abbott of evYsio's stent design.
Implanted devices that use wireless technology are vulnerable to being `hacked,' or accessed in an unauthorized manner, a new study finds. The authors of the study, which was performed on a lab bench and not in live patients, were able to send unauthorized commands to wireless devices such as pacemakers and implantable cardioverter-defibrillators. These commandsÂ enabled them toÂ reprogram settings, retrieve patient data, and even deliver potentially fatal shocks.
For more than a year, drug-eluting stents have been battered by a storm of negative publicity that questioned the efficacy and safety of the devices. Having captured almost 90% of the coronary stent market shortly after receiving FDA approval, drug-eluting stents experienced a precipitous decline...
Originally Published MPMN July 2006 INDUSTRY NEWS University Researchers Create Artificial Compound Eyes A magnified image of an artificial compound eye shows some of the 8700 hexagonal microlenses that make up its surface. Photo courtesy of Science Magazine/Luke Lee. Artificial compound eyes that...
Guidant Corp. suffered yet another setback yesterday when it announced it would scrap its drug-eluting stent slated for introduction in Europe because of manufacturing defects. The New York Times reports that European introduction of the Xience V stent has been pushed back to the third quarter of this year, and the company has taken a $15 million write-off for the first quarter.